...
alny-img

Alnylam Pharmaceuticals Inc, Common Stock

ALNY

NSQ

$243.25

+$0.99

(0.41%)

1D
Industry: Biotechnology Sector: Health Care

Analyst Forecast

Price Chart

Key Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$31.37B
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
0
Volume info-icon
This is the total number of shares traded during the most recent trading day.
0
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
0.39
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$141.98 L
$304.39 H
$243.25

About Alnylam Pharmaceuticals Inc, Common Stock

Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1. In addition, the company develops patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; cemdisiran to treat complement-mediated diseases; Belcesiran for the treatment of alpha-1 liver disease; Elebsiran to treat chronic HBV infection; Zilebesiran to treat hypertension; ALN-APP to treat Alzheimer's disease and cerebral amyloid angiopathy; and ALN-HSD to treat NASH. Further, it offers Fitusiran for the treatment of hemophilia, Inclisiran to treat hypercholesterolemia, lumasiran for the treatment of advanced PH1, and vutrisiran for the treatment of ATTR amyloidosis, which is in phase 3 clinical trial. Alnylam Pharmaceuticals, Inc. has strategic collaborations with Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for a range of diseases by addressing therapeutic targets expressed in the eye and CNS; and Roche to develop pharmaceutical products containing zilebesiran. It also has license and collaboration agreements with Novartis AG; Vir Biotechnology, Inc.; Dicerna Pharmaceuticals, Inc.; Ionis Pharmaceuticals, Inc.; and PeptiDream, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts. more

Industry: BiotechnologySector: Health Care

Returns

Time FrameALNYSectorS&P500
1-Week Return-1.35%-0.33%-1.49%
1-Month Return-3.08%-4.57%-0.37%
3-Month Return-10.24%-9.96%3.89%
6-Month Return9.13%-5.67%9.34%
1-Year Return27.22%2.53%25.19%
3-Year Return50.98%-1.43%24.7%
5-Year Return106.69%34.73%85.39%
10-Year Return160.1%102.14%187.19%

Financials

Dec '19Dec '20Dec '21Dec '22Dec '235YR TREND
Total Revenue219.75M492.85M844.29M1.04B1.83B[{"date":"2019-12-31","value":12.02,"profit":true},{"date":"2020-12-31","value":26.96,"profit":true},{"date":"2021-12-31","value":46.18,"profit":true},{"date":"2022-12-31","value":56.74,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Cost of Revenue25.06M78.05M140.14M168.82M310.41M[{"date":"2019-12-31","value":8.07,"profit":true},{"date":"2020-12-31","value":25.15,"profit":true},{"date":"2021-12-31","value":45.15,"profit":true},{"date":"2022-12-31","value":54.39,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Gross Profit194.69M414.80M704.14M868.60M1.52B[{"date":"2019-12-31","value":12.83,"profit":true},{"date":"2020-12-31","value":27.33,"profit":true},{"date":"2021-12-31","value":46.39,"profit":true},{"date":"2022-12-31","value":57.22,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Gross Margin88.60%84.16%83.40%83.73%83.02%[{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":95,"profit":true},{"date":"2021-12-31","value":94.14,"profit":true},{"date":"2022-12-31","value":94.51,"profit":true},{"date":"2023-12-31","value":93.71,"profit":true}]
Operating Expenses1.13B1.24B1.41B1.65B1.80B[{"date":"2019-12-31","value":63,"profit":true},{"date":"2020-12-31","value":69.07,"profit":true},{"date":"2021-12-31","value":78.49,"profit":true},{"date":"2022-12-31","value":91.87,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Operating Income(939.43M)(828.44M)(708.65M)(785.07M)(282.18M)[{"date":"2019-12-31","value":-93943100000,"profit":false},{"date":"2020-12-31","value":-82843800000,"profit":false},{"date":"2021-12-31","value":-70865200000,"profit":false},{"date":"2022-12-31","value":-78507200000,"profit":false},{"date":"2023-12-31","value":-28217500000,"profit":false}]
Total Non-Operating Income/Expense87.63M(99.85M)(284.93M)(473.08M)(177.00M)[{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":-113.95,"profit":false},{"date":"2021-12-31","value":-325.17,"profit":false},{"date":"2022-12-31","value":-539.89,"profit":false},{"date":"2023-12-31","value":-202,"profit":false}]
Pre-Tax Income(885.25M)(855.60M)(852.14M)(1.13B)(433.52M)[{"date":"2019-12-31","value":-88525300000,"profit":false},{"date":"2020-12-31","value":-85560000000,"profit":false},{"date":"2021-12-31","value":-85214400000,"profit":false},{"date":"2022-12-31","value":-112699300000,"profit":false},{"date":"2023-12-31","value":-43351700000,"profit":false}]
Income Taxes863.00K2.68M680.00K4.16M6.72M[{"date":"2019-12-31","value":12.83,"profit":true},{"date":"2020-12-31","value":39.87,"profit":true},{"date":"2021-12-31","value":10.11,"profit":true},{"date":"2022-12-31","value":61.9,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Income After Taxes(886.12M)(858.28M)(852.82M)(1.13B)(440.24M)[{"date":"2019-12-31","value":-88611600000,"profit":false},{"date":"2020-12-31","value":-85828100000,"profit":false},{"date":"2021-12-31","value":-85282400000,"profit":false},{"date":"2022-12-31","value":-113115600000,"profit":false},{"date":"2023-12-31","value":-44024200000,"profit":false}]
Income From Continuous Operations(886.12M)(858.28M)(852.82M)(1.13B)(440.24M)[{"date":"2019-12-31","value":-88611600000,"profit":false},{"date":"2020-12-31","value":-85828100000,"profit":false},{"date":"2021-12-31","value":-85282400000,"profit":false},{"date":"2022-12-31","value":-113115600000,"profit":false},{"date":"2023-12-31","value":-44024200000,"profit":false}]
Income From Discontinued Operations-----[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Net Income(886.12M)(858.28M)(852.82M)(1.13B)(440.24M)[{"date":"2019-12-31","value":-88611600000,"profit":false},{"date":"2020-12-31","value":-85828100000,"profit":false},{"date":"2021-12-31","value":-85282400000,"profit":false},{"date":"2022-12-31","value":-113115600000,"profit":false},{"date":"2023-12-31","value":-44024200000,"profit":false}]
EPS (Diluted)(8.15)(7.66)(7.12)(8.66)(3.56)[{"date":"2019-12-31","value":-815,"profit":false},{"date":"2020-12-31","value":-766,"profit":false},{"date":"2021-12-31","value":-712,"profit":false},{"date":"2022-12-31","value":-866,"profit":false},{"date":"2023-12-31","value":-356,"profit":false}]

Ratios

Liquidity

These ratios help you determine the liquidity of the company. Higher is better.

ALNY
Cash Ratio 2.27
Current Ratio 2.75
Quick Ratio 2.69

Asset Efficiency

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

ALNY
ROA (LTM) -2.92%
ROE (LTM) -1500.66%

Liabilities

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

ALNY
Debt Ratio Lower is generally better. Negative is bad. 0.99
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. 0.01

Valuation

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

ALNY
Trailing PE NM
Forward PE 909.09
P/S (TTM) 14.98
P/B 965.78
Price/FCF 794
EV/R 14.21
EV/Ebitda 204.85
PEG NM

FAQs

What is Alnylam Pharmaceuticals Inc share price today?

Alnylam Pharmaceuticals Inc (ALNY) share price today is $243.25

Can Indians buy Alnylam Pharmaceuticals Inc shares?

Yes, Indians can buy shares of Alnylam Pharmaceuticals Inc (ALNY) on Vested. To buy Alnylam Pharmaceuticals Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in ALNY stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of Alnylam Pharmaceuticals Inc be purchased?

Yes, you can purchase fractional shares of Alnylam Pharmaceuticals Inc (ALNY) via the Vested app. You can start investing in Alnylam Pharmaceuticals Inc (ALNY) with a minimum investment of $1.

How to invest in Alnylam Pharmaceuticals Inc shares from India?

You can invest in shares of Alnylam Pharmaceuticals Inc (ALNY) via Vested in three simple steps:

  • Click on Sign Up or Invest in ALNY stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in Alnylam Pharmaceuticals Inc shares
What is Alnylam Pharmaceuticals Inc 52-week high and low stock price?

The 52-week high price of Alnylam Pharmaceuticals Inc (ALNY) is $304.39. The 52-week low price of Alnylam Pharmaceuticals Inc (ALNY) is $141.98.

What is Alnylam Pharmaceuticals Inc price-to-earnings (P/E) ratio?

The price-to-earnings (P/E) ratio of Alnylam Pharmaceuticals Inc (ALNY) is

What is Alnylam Pharmaceuticals Inc price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of Alnylam Pharmaceuticals Inc (ALNY) is 965.78

What is Alnylam Pharmaceuticals Inc dividend yield?

The dividend yield of Alnylam Pharmaceuticals Inc (ALNY) is 0.00%

What is the Market Cap of Alnylam Pharmaceuticals Inc?

The market capitalization of Alnylam Pharmaceuticals Inc (ALNY) is $31.37B

What is Alnylam Pharmaceuticals Inc’s stock symbol?

The stock symbol (or ticker) of Alnylam Pharmaceuticals Inc is ALNY

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top